Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4550710 | 0.91 | ADRA1A (0.46) | DGAT1TRPV1ADRA1ACRHBPCRHR2 | |
| SCHEMBL4415368 | 0.79 | CRHBP (0.42) | CRHBPCRHR2MEN1KMT2ANPY5R | |
| SCHEMBL4418680 | 0.78 | TRPV1 (0.39) | TRPV1CRHBPCRHR2NPY5RSMN1; SMN2 | |
| SCHEMBL4552442 | 0.78 | MEN1 (0.34) | CRHBPCRHR2MEN1KMT2ATSHR | |
| SCHEMBL2179917 | 0.77 | LMNA (0.35) | DGAT1ADRA1AMEN1KMT2ALMNA | |
| SCHEMBL18887325 | 0.76 | LMNA (0.33) | DGAT1ADRA1AMEN1KMT2ALMNA | |
| SCHEMBL4415691 | 0.76 | TRPV1 (0.52) | TRPV1CRHBPCRHR2MEN1KMT2A | |
| SCHEMBL4418781 | 0.75 | TSHR (0.44) | CRHBPCRHR2MEN1KMT2ATSHR | |
| SCHEMBL4415708 | 0.75 | SMN1; SMN2 (0.51) | TRPV1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL4414893 | 0.75 | HIF1A (0.50) | CRHBPCRHR2MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680124-B1 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | PFIZER PROD INC (US) | 2017-05-31 | — | — | EP | claimed |
| US-20050096375-A1 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | PFIZER INC. | 2005-05-05 | — | — | US | claimed |
| EP-1680124-B1 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | PFIZER PROD INC (US) | 2017-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096375-A1 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | SLC6A5, SLC1A5, SLC6A3 | DGAT1 720/4885TRPV1 1359/4885ADRA1A 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.